Taysha Gene Therapies, Inc.
Company Stats
- Market Cap
- $1.6B
- as of Sep 30, 2026
- Enterprise Value
- $1.3B
- Shares Outstanding
- 325.8M
- Free Float
- 84.0%
Income Statement
- Revenue
- $9.8M
- Operating Income
- -$110.5M
- Net Income
- -$109.0M
- EBITDA
- -$109.4M
- Revenue Growth, 3Y
- 57.5%
- FCF Margin, 3Y Avg
- -812.3%
- FCF Margin, Worst Year
- -979.2%
Cash Flow
- Free Cash Flow
- -$93.8M
- FCF Yield
- -5.9%
- Owner FCF Yield
- -6.8%
Balance Sheet
- Cash & Equivalents
- $319.8M
- Total Debt
- $50.0M
- Net Cash
- $269.8M
Returns & Capital
- SBC, 3Y Avg
- $11.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $9.8M | -$93.8M | -960.1% |
| FY2024 | $8.3M | -$81.6M | -979.2% |
| FY2023 | $15.5M | -$76.9M | -497.6% |
| FY2022 | $2.5M | -$109.0M | -4356.9% |
| FY2021 | — | -$132.3M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
BlackBerry Hits Cash Flow Milestone; M&A Hits Life Sciences, AI